Edgewise Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Edgewise Therapeutics

31/07/2023 14:01

* Edgewise Therapeutics Inc  EWTX.OQ   EWTX.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 2 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Edgewise
Therapeutics Inc
is for a loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Edgewise
Therapeutics Inc is $27.5​, above​ its last closing price
of $7.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.35       -0.36      -0.36     Met     0
 Dec. 31 2023  -0.34       -0.34      -0.31     Beat    7.7
 Sep. 30 2022  -0.35       -0.36      -0.34     Beat    4.5​
 Jun. 30 2022  -0.33       -0.32      -0.32     Met     1.2
 ​​Mar.        -0.28       -0.28      -0.30     Missed  -7.9
 31 2022                                                
 Dec. 31 2021  -0.24       -0.25      -0.26     Missed  -5.1​
 Sep. 30 2021  -0.24       -0.22      -0.26     Missed  -16.4
 Jun. 30 2021  -0.18       -0.18      -0.21     Missed  -18.3
 This summary was machine generated July 31 at 13:01 GMT.  All
figures in US dollars  unless otherwise stated